Sanofi

C M Industries

Sanofi (societe Anonyme)

Franz K Jansen

Pierre Gros

Pierre Casellas

Guy Voisin

Prolonged-action immunotoxin consisting of a conjugate in which an antibody or antibody fragment is coupled, by means of a covalent structure containing a disulfide group or a thioether group, with a glycoprotein which inactivates ribosomes and has a prolonged action obtained by the oxidation of its saccharide units which periodate ions.

Prolonged-action immunotoxins containing a glycopeptide constituent

The present invention relates to conjugates in which a monovalent carboxylic ionophore is associated by means of a covalent bond with a macromolecule chosen from antibodies, fragments of antibodies, proteins such as peptide hormones or human proteins, and peptide ligands. It also relates to the activated inophores. These conjugates are suitable as immunotoxin potentiators.

Conjugates in which a monovalent carboxylic ionophore is associated by

Immunotoxins formed by the covalent coupling of, on the one hand, the A chain of ricin, as such or correctly modified, with, on the other hand, an antibody or a fragment of an antibody, used in its natural form or correctly modified, which possesses the capacity to selectively recognize an antigen carried by the intended target cells. The coupling is effected either via a disulfide bond or via a thioether bond, with the limitation that, when the coupling is effected via a disulfide and one of the sulfur atoms is that belonging to the A chain of ricin, the other sulfur is bonded to the antibody by a spacing structure which is itself bonded to a group of the protein other than an amine group.

Cytotoxic conjugates which can be used in therapy and process for their

The present invention relates to conjugates in which a monovalent carboxylic ionophore is associated by means of a covalent bond with a macromolecule chosen from antibodies, fragments of antibodies, proteins such as peptide hormones or human proteins, and peptide ligands. It also relates to the activated ionophores. These conjugates are suitable as immunotoxin potentiators.

The present invention relates to conjugates in which a monovalent carboxylic ionophore is associated by means of a covalent bond with a macromolecule chosen from antibodies, fragments of antibodies, and peptide ligands. It also relates to the activated ionophores. These conjugates are suitable as immunotoxin potentiators.

The present invention relates to a process for potentiating the activity of a conjugate consisting of the A chain of ricin coupled with an antibody directed against human T cells, the said process consisting in adding an effective quality of ammonium chloride to the said conjugate.

Process for the potentiation of immunotoxins

The invention relates to a cytotoxic pharmaceutical combination comprising:

Appropriate cytotoxic pharmaceutical combination especially for the

The present invention relates to drugs characterized in that they comprise, in association, at least one immunotoxin and at least one monovalent carboxylic ionophore.

Drugs comprising in association at least one immunotoxin and at least

The present invention relates to new immunoenzymic conjugates resulting from a chemical coupling, by covalent bond, of an antibody or a fragment of antibody, which has retained the capacity of recognizing the selected antigen, with an enzyme capable of producing ammonium ions from natural substrates which are well tolerated in higher animal organisms. The invention also relates to a process for the preparation of these conjugates and the medicinal associations of said conjugates with an immunotoxin.

New conjugates associating, by covalent bond, an enzyme with an

Imidazolides of the formula: ##STR1## in which: E represents an inert spacing structure; and

Imidazolides as intermediates for the synthesis of cytotoxic conjugates

The present invention relates to an anti-cancer drug, characterized in that it contains at least one product constituted by the chain A of recin conjugated by means of a disulfide bridge with at least one fraction of a monoclonal antibody of leukaemic anti-cell specificity, and to the processes for preparing the active ingredient of said drug.

Anti-cancer drugs for the treatment of leukaemias I, constituted by the

Cytotoxic composition including at least an immunotoxine and an amine

Cytotoxic medicament formed from the association of at least one

The present invention relates to drugs useful in particular for the treatment of melanomas, characterized in that they contain an active substance which is a molecule in which the chain A of ricin is associated, by a covalent bond of disulfide type, with a human antimelanoma antibody.

Anti-cancer drugs for the treatment of melanomas and method for

Carcinostatic products are formed by coupling, by covalent bonding, the A chain of ricin with an antibody which is capable of selectively recognizing a given antigen at the surface of cancerous cells. Such products can be made by the formation of a disulphide bridge between the free thiol group in the A chain of ricin and an immunoglobulin or immunoglobulin fragment into which a thiol group or an activated disulphide group has been introduced. The A chain of ricin and the immunoglobulin are carefully purified before use.

Growing community of inventors

Castries, France

Franz K Jansen